On the problems of treatment of uterine sarcoma

Mariam Gablishvili, Maia Mchedlishvili



Introduction: Present article is aimed at discussing the efficacy of the traditional treatment of uterine sarcoma, such as surgery and chemotherapy, as well as the significance of the  expression of  programmed cell death receptor-1/ligand 1  and sex hormone receptors (estrogen and progesterone receptors) in prognosis of the uterine sarcoma outcome. Method: Data was collected using the electronic search method in the following databases: PubMed/Medline, Web of Science. Terms “Uterine sarcoma”, immunotherapy”, “Immunohystology” were utilized. Articles published between 2005-2021 were included.  Conclusion: Existing data on surgical approach vary from radical hysterectomy to fertility-preserving surgery in the form of trachelectomy or wide local excision, however no definite conclusions can be drafted on the recommended surgical approach. There is a controversy in findings concerning the prognostic value  of sex hormone (estrogen and progesterone) receptors and programmed cell death receptor-1/ligand 1 expression in the treatment of uterine sarcomas. Extension of data in this direction is necessary to throw more light to the role of truditional treatment methods and onco-immunology in the treatment of uterine sarcoma.


Uterus; Sarcoma;Onco-immunology

Full Text:



Nathenson MJ, Conley A. P, Sausville E. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. The oncologist. 2018; 23(1): 71–83.

National Cancer Institute. Seer Cancer Statistics Review, 1975–2012. Available at http://seer.cancer.gov/csr/1975_2012/. Accessed April 2015.

Naaman Y, Shveiky D, Ben-Shachar I, Shushan A et al. Uterine sarcoma: prognostic factors and treatment evaluation. Israel Medical Association Journal. 2011; 13(2):76-9.

Benson C, Miah AB. Uterine sarcoma - current perspectives. International journal of women's health, 2017; 9, 597–606.

Desar LM, Ottevanger PB , Benson C., van der Graaf W. Systemic treatment in adult uterine sarcomas. Critical Reviews in Oncology/Hematology. 2017;122, 10-20.

Giuntoli RL, 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–88.

Ghirardi, V., Bizzarri, N., Guida, F., Vascone, C., Costantini, B., Scambia, G., & Fagotti, A. (2019). Role of surgery in gynaecological sarcomas. Oncotarget, 10(26), 2561–2575. https://doi.org/10.18632/oncotarget.26803

Nakamura K, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sekiya R, Sakata J, Yamamoto E, Shibata K, Kikkawa F. Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas. Mol Clin Oncol. 2018;8:499–503. doi: 10.3892/mco.2018.1560.

Díaz-Montes TP, El-Sharkawy F, Lynam S, Harper A, Sittig M, MacDonald R, Gushchin V, Sardi A. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. Int J Gynecol Cancer. 2018;28:1130–37.

Parra-Herran C, Howitt BE. Uterine Mesenchymal Tumors: Update on Classification, Staging, and Molecular Features. Surgical Pathology Clinics. 2019; 12 (2):363-396.

Momeni-Boroujeni A, Chiang S. Uterine mesenchymal tumors: recent advances. Histopathology. 2020; 76 (1): 64-75.

Davidson B, Kjæreng M, Førsund M et al., Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. American Journal of Clinical Pathology. 2016; 145 (4): 449–458.

Koivisto-Korander R., Butzow R., Koivisto AM et al. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biology. 2011; 32, 451–459.

Li D, Yin N, Du G, Xiao Z, Chen J, Chen W. A real-world study on diagnosis and treatment of uterine sarcoma in Western China. International Journal of Biological Science. 2020; 16, (3), 338-395.

Italiano A., Bellera C, D’Angelo S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. Journal of Hematology Oncology. 2020; 13, (55):, 2-4.


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)